Abstract
Crystalline and amorphous dispersions have been the focus of academic and industrial research due to their potential role in formulating poorly water-soluble drugs. This review looks at the progress made starting with crystalline carriers in the form of eutectics moving towards more complex crystalline mixtures. It also covers using glassy polymers to maintain the drug as amorphous exhibiting higher energy and entropy. However, the amorphous form tends to recrystallize on storage, which limits the benefits of this approach. Specific interactions between the drug and the polymer may retard this spontaneous conversion of the amorphous drug. Some studies have shown that it is possible to maintain the drug in the amorphous form for extended periods of time. For the drug and the polymer to form a stable mixture they have to be miscible on a molecular basis. Another form of solid dispersions is pharmaceutical co-crystals, for which research has focused on understanding the chemistry, crystal engineering and physico-chemical properties. USFDA has issued a guidance in April 2013 suggesting that the co-crystals as a pharmaceutical product may be a reality; but just not yet! While some of the research is still oriented towards application of these carriers, understanding the mechanism by which drug-carrier miscibility occurs is also covered. Within this context is the use of thermodynamic models such as Flory-Huggins model with some examples of studies used to predict miscibility.
Keywords: Solid dispersions, milling, surfactants, saturation solubility, thermal analysis, co-crystals.
Current Pharmaceutical Design
Title:Amorphous and Crystalline Particulates: Challenges and Perspectives in Drug Delivery
Volume: 23 Issue: 3
Author(s): Hisham Al-Obaidi, Mridul Majumder and Fiza Bari
Affiliation:
Keywords: Solid dispersions, milling, surfactants, saturation solubility, thermal analysis, co-crystals.
Abstract: Crystalline and amorphous dispersions have been the focus of academic and industrial research due to their potential role in formulating poorly water-soluble drugs. This review looks at the progress made starting with crystalline carriers in the form of eutectics moving towards more complex crystalline mixtures. It also covers using glassy polymers to maintain the drug as amorphous exhibiting higher energy and entropy. However, the amorphous form tends to recrystallize on storage, which limits the benefits of this approach. Specific interactions between the drug and the polymer may retard this spontaneous conversion of the amorphous drug. Some studies have shown that it is possible to maintain the drug in the amorphous form for extended periods of time. For the drug and the polymer to form a stable mixture they have to be miscible on a molecular basis. Another form of solid dispersions is pharmaceutical co-crystals, for which research has focused on understanding the chemistry, crystal engineering and physico-chemical properties. USFDA has issued a guidance in April 2013 suggesting that the co-crystals as a pharmaceutical product may be a reality; but just not yet! While some of the research is still oriented towards application of these carriers, understanding the mechanism by which drug-carrier miscibility occurs is also covered. Within this context is the use of thermodynamic models such as Flory-Huggins model with some examples of studies used to predict miscibility.
Export Options
About this article
Cite this article as:
Al-Obaidi Hisham, Majumder Mridul and Bari Fiza, Amorphous and Crystalline Particulates: Challenges and Perspectives in Drug Delivery, Current Pharmaceutical Design 2017; 23 (3) . https://dx.doi.org/10.2174/1381612822666161107162109
DOI https://dx.doi.org/10.2174/1381612822666161107162109 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Small Molecule Approaches for Promoting Neurogenesis
Current Alzheimer Research Effects of Engineered Type I Collagen on Hepatocyte Cultures
Current Nanoscience The Resting-State Functional Connectivity of the Default Mode Networks in Patients With Obstructive Sleep Apnea-Hypopnea Syndrome
CNS & Neurological Disorders - Drug Targets Inhibition of Store-Operated Calcium Entry in Alzheimer’s Disease and the Associated Mechanisms
Current Alzheimer Research Management of Ovarian Cancer in Elderly
Reviews on Recent Clinical Trials Preface
CNS & Neurological Disorders - Drug Targets Application of Monoterpenoids and their Derivatives for Treatment of Neurodegenerative Disorders
Current Medicinal Chemistry The Neuropharmacology of Implicit Learning
Current Neuropharmacology Immune Response to Mycobacteria
Current Immunology Reviews (Discontinued) Therapy of No-Type I Bipolar Spectrum Disorders: A Systematic Review
Current Psychiatry Reviews Mediators of Tyrosine Phosphorylation in Innate Immunity: From Host Defense to Inflammation onto Oncogenesis
Current Signal Transduction Therapy Promoting Well-being and Resilience in Employing a Relationship Centered Approach: A Case Study of a Pre-adolescent Boy
Adolescent Psychiatry Targeting Dopaminergic System for Treating Nicotine Dependence
Central Nervous System Agents in Medicinal Chemistry Therapeutic Targeting of the Endoplasmic Reticulum in Alzheimers Disease
Current Alzheimer Research Alcohol Abuse and HIV Infection: Role of DRD2
Current HIV Research Differential Contribution of Clinical Amounts of Acetaldehyde to Skeletal and Cardiac Muscle Dysfunction in Alcoholic Myopathy
Current Pharmaceutical Design Antisense Technology: A Selective Tool for Gene Expression Regulation and Gene Targeting
Current Pharmaceutical Biotechnology Advances in Zebrafish High Content and High Throughput Technologies
Combinatorial Chemistry & High Throughput Screening Disequilibrium and Risk of Falling in the Elderly is a Priority for Health Services
Reviews on Recent Clinical Trials BDNF/NF-κB Signaling in the Neurobiology of Depression
Current Pharmaceutical Design